z-logo
open-access-imgOpen Access
Use of monoclonal antibodies as sensitive and specific probes for biologically active human gamma-interferon.
Author(s) -
Tse Wen Chang,
Sam McKinney,
Victor Liu,
Patrick Kung,
Ján Vilček,
Junming Le
Publication year - 1984
Publication title -
proceedings of the national academy of sciences of the united states of america
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 5.011
H-Index - 771
eISSN - 1091-6490
pISSN - 0027-8424
DOI - 10.1073/pnas.81.16.5219
Subject(s) - immunoradiometric assay , monoclonal antibody , recombinant dna , antibody , microbiology and biotechnology , epitope , chemistry , interferon gamma , biological activity , escherichia coli , radioimmunoassay , biology , biochemistry , in vitro , immunology , gene
Mouse monoclonal antibodies B1 and B3 are specific for natural and Escherichia coli-derived recombinant human gamma-interferon (IFN-gamma). The two antibodies recognize different epitopes of the IFN-gamma molecule and do not compete with each other's binding. We have used these two antibodies to construct a solid-phase, sandwich immunoradiometric assay for human IFN-gamma. Purified antibody B1 was coated on polystyrene beads (0.64 cm in diameter) and used as the solid-phase immunoadsorbent and antibody B3 was labeled with 125I and used as tracer. This assay can be completed in about 4 hr and is capable of detecting IFN-gamma levels in human serum or tissue culture fluids as low as 0.1 NIH reference unit/ml. Recombinant human IFN-gamma derived from E. coli was detectable at a concentration of 0.02 ng/ml. The assay appears to be specific for the biologically active forms of IFN-gamma, since after exposure to pH 2, 37 degrees C, or 56 degrees C, biological activity and reactivity in the immunoradiometric assay decreased in parallel. The immunoradiometric assay can be employed for the analysis of the structural characteristics of the human IFN-gamma molecule.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here